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A study of compressibility and compactibility 
of directly compressible tableting materials containing 
tramadol hydrochloride
The paper evaluates and compares the compressibility and 
compactibility of directly compressible tableting materials 
for the preparation of hydrophilic gel matrix tablets con-
taining tramadol hydrochloride and the coprocessed dry 
binders Prosolv® SMCC 90 and Disintequik™ MCC 25. The 
selected types of hypromellose are Methocel™ Premium 
K4M and Methocel™ Premium K100M in 30 and 50 % con-
centrations, the lubricant being magnesium stearate in a 1 % 
concentration. Compressibility is evaluated by means of the 
energy profile of compression process and compactibility 
by the tensile strength of tablets.
The values of total energy of compression and plasticity were 
higher in the tableting materials containing Prosolv® SMCC 
90 than in those containing Disintequik™ MCC 25. Tramadol 
slightly decreased the values of total energy of compression 
and plasticity. Tableting materials containing Prosolv® SMCC 
90 yielded stronger tablets. Tramadol decreased the strength 
of tablets from both coprocessed dry binders.
Keywords: tramadol hydrochloride, hydrophilic matrix tab-
lets, coprocessed dry binder, hypromellose, energy profile 
of compression, tensile strength of tablets
Dosage forms with prolonged release of the active ingredient represent a contemporary 
trend, prolonged-release tablets being an important form. One of its technological types are 
matrix tablets, in which the active ingredient including the retarding component is distrib-
uted throughout the whole matrix of the tablet. According to the type of the retarding 
component, matrix tablets are classified as polymeric insoluble, hydrophilic gel, lipophilic, 
or mixed (1). The simplest method of producing matrix tablets is direct compression. Direct 
compression requires excipients called dry binders, which fulfil the function of filler and 
binder at the same time (2). Several dry binders are sometimes present, or the dry binder 
and another excipient are combined to form one substance by the so-called coprocessing 
and give rise to coprocessed dry binders. These substances are aimed at increasing the 
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positive properties of individual ingredients and suppressing the negative ones. They may 
also be of multifunctional character (3). Dry binders include also substances considered in 
this study, i.e., Prosolv® SMCC 90 and Disintequik™ MCC 25. Prosolv® SMCC is silicified 
microcrystalline cellulose (SMCC) containing 98 % of microcrystalline cellulose (MCC) and 
2 % of colloidal silicon dioxide in a patented homogeneous mixture. It shows some advan-
tages, such as good flow properties, a short period of disintegration, and high mechanical 
strength of tablets resulting from the intersurface interaction of silicon dioxide and MCC (4, 
5). In coprocessing, colloidal silicon dioxide is uniformly dispersed over microcrystalline 
cellulose and forms a rough surface of SMCC in comparison with MCC, the surface of which 
is much smoother and smaller (6). Prosolv® SMCC 90 contains particles of an average size of 
110 μm, which ensures good flowability and also suitability for direct compression (7). 
Disintequik™ MCC 25 is a relatively new coprocessed dry binder containing 75 % of 
α-lactose monohydrate and 25 % of microcrystalline cellulose (8). This combination of sub-
stances is employed because of their synergic effect, which consists of greater strength and 
rapid disintegration of tablets. The lactose present is a fragile material, in which fragmenta-
tion takes place, thus providing areas for the development of new bonds. MCC is character-
ized by plastic deformation and enables rapid disintegration of tablets (9). Disintequik™ 
MCC 25 is characterized by better flow properties, which support mass uniformity of tablets 
and better compressibility than in the physical mixture of lactose and microcrystalline cel-
lulose (8). Hydrophilic gel matrix tablets also contain an auxiliary gel-forming substance, 
which decelerates the release of the active ingredient. This excipient is very often hyprom-
ellose, which comes in several viscosity degrees (10). Examples are the products of Metho-
cel™ Premium K4M and K100M, which were employed in this study.
The aim of this paper was to study compressibility and compactibility of directly 
compressible tableting materials intended for preparation of hydrophilic gel matrix tablets 
with tramadol hydrochloride. Tableting materials tested included two types of copro-
cessed dry binders and two viscosity types of hypromellose in concentrations of 30 and 50 
%. Compressibility was evaluated by means of the energy profile of the compression pro-
cess and compactibility by the tensile strength of tablets.
EXPERIMENTAL
Materials
Silicified microcrystalline cellulose Prosolv® SMCC 90 was supplied by JRS Pharma, 
GmbH+Co.kG (Germany), Disintequik™ MCC 25 by Kerry (USA), hypromellose (Metho-
cel™ K4M Premium CR, Methocel™ K100M Premium CR) by the firm Colorcon GmbH 
(Germany). Magnesium stearate was obtained from Acros Organics (USA). Tramadol hy-
drochloride was from Sigma-Aldrich (Czech Republic).
Preparation of tableting materials
Altogether sixteen tableting materials of the following compositions were prepared 
and tested (Table I).
Tableting materials were prepared using a mixing cube KB 15S (Erweka GmbH, Ger-
many). The mixing rate was 17 rot/min. The appropriate type of Methocel™ with Prosolv® 
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SMCC 90 or Disintequik™ MCC 25 was first mixed for a period of 5 minutes. Tramadol was 
then added for another 5 minutes, and finally magnesium stearate was added for a mixing 
period of 2.5 minutes. Mixtures without the active ingredient were prepared in the same 
manner without the mixing step with tramadol, their mass being 20 g. The mass of tablet-
ing materials with tramadol was 30 g.
Preparation of tablets and energy evaluation of compression process
Tablets were compressed using a material testing equipment T1-FRO 50 TH.A1K 
Zwick/Roell (Zwick GmbH & Co, Germany) by means of a special die with a lower and an 
upper punch. The rate of compaction was 40 mm min–1, pre-load was 2 N, and the rate of 
preload was 2 mm s–1. The tablets were of cylindrical shape without facets, with a 13 mm 
diameter, m = 0.5000 ± 0.0010 g. The employed compression force was 5 kN. At this com-
pression force, 10 tablets were compressed. The computer program testXpert V 9.01 (Zwick 
GmbH&Co) simultaneously recorded the energy process of compression by means of the 
„force-displacement” record and numerically evaluated the energy balance of compres-
sion, i.e., the energy of precompression E1, energy of plastic deformation E2, and energy of 
elastic deformation E3, energy of compression Ecom, which is the sum of E2 and E3, total 
energy Emax, which is the sum of all energies, and plasticity (11, 12).
Table I. Composition of tableting materials (%)
Tableting 
material P 90 D 25 Tramadol M4M M100M Mgst
1 49 20 30 1
2 29 20 50 1
3 49 20 30 1
4 29 20 50 1
5 69 30 1
6 49 50 1
7 69 30 1
8 49 50 1
9 49 20 30 1
10 29 20 50 1
11 49 20 30 1
12 29 20 50 1
13 69 30 1
14 49 50 1
15 69 30 1
16 49 50 1
P 90 – Prosolv SMCC 90, D 25 – Disintequik MCC 25, M4M – Methocel K4M Premium CR, M100M – Methocel K100M 
Premium CR, Mgst – magnesium stearate
436
J. Mužíková and A. Kubíčková: A study of compressibility and compactibility of directly compressible tableting materials containing 
tramadol hydrochloride, Acta Pharm. 66 (2016) 433–441.
 
Measurement of tablet tensile strength
Tensile strength of tablets was measured in 10 tablets no sooner than 24 hours after 
compression (tablets were stored in plastic tubes). Measurements were performed using a 
Schleuniger apparatus (Dr. Schleuniger Pharmatron AG, Switzerland), which measures the 
diameter and height of tablets with a precision of 0.01 mm and destruction force in N. Tensile 
strength of tablets was subsequently calculated according to the equation (Eq. 1) (13):
 P = 2 F/(π d h)    (1)
where P is tensile strength of tablets in MPa, F is destruction force in N, d is tablet diameter 
in mm, h is tablet height in mm.
Mathematical and statistical processing of results
The results of tensile strengths of tablets were statistically processed by means of the 
computer programs Excel and Qcexpert (TriloByte Statistical Software, s.r.o., Czech Re-
public). The energy and plasticity values were statistically processed by the computer 
program testXpert V 9.01 (Zwick GmbH&Co, Germany) directly during compaction. In the 
case of similar significance of values, an ANOVA test at a level of significance of 0.05 was 
employed.
RESULTS AND DISCUSSION
The aim of the paper is to evaluate the compressibility and compactibility of directly 
compressible tableting materials containing the active ingredient tramadol hydrochloride, 
two types of coprocessed dry binders and two types of hypromellose differing in the viscos-
ity degree. The coprocessed dry binders employed were Prosolv® SMCC 90, which is silici-
fied microcrystalline cellulose with 2 % of colloidal magnesium dioxide, and Disintequik™ 
MCC 25, which contains 75 % of α-lactose monohydrate and 25 % of microcrystalline cellu-
lose. In the function of hypromellose, i.e., the substance decelerating the release of the active 
ingredient, Methocel™ Premium K4M and Methocel™ Premium K100M in concentrations 
of 30 and 50 % were used. The lubricant employed in all tableting materials was magnesium 
stearate in a concentration of 1 %. Compressibility was evaluated by means of the energy 
profile of the compression process and compactibility by tensile strength of tablets. The 
compression force of 5 kN was selected in such a way as to maintain the strength of the 
compacts from the tableting materials with both coprocessed dry binders higher than the 
lower limit of the optimal tensile strength of tablets, which is 0.56 MPa (14).
Energy profile of compression process
Values of the energy profile of the compression process at the compression force of 5 
kN are shown in Tables II and III. Values of the tableting materials with Prosolv SMCC 90 
are presented in Table II and the values for the tableting materials with Disintequik MCC 
25 are given in Table III. In the tableting materials without the active ingredient, the values 
of the total energy Emax are higher for the tableting materials with Prosolv SMCC 90, where 
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there is no statistically significant difference between them (p = 0.094). In the case of Dis-
intequik MCC 25, there is no clear difference between the values within the same concen-
tration of different types of Methocel (30 % of Methocel p = 0.054; 50 % of Methocel p = 
0.143). A more marked difference in values is observed in the use of the same type of 
Methocel in different concentrations, when 50 % concentration of Methocel in the tableting 
material produces higher values of Emax than the 30 % concentration. Tramadol in the 
tableting materials with Proslov SMCC 90 decreases the Emax values, but there is no marked 
difference in the values within the type and concentration of hypromellose employed (p = 
0.099). In the case of tableting materials with Disintequik MCC 25, the Emax values are less 
decreased by the action of tramadol and the influence of different concentrations of hypro-
mellose is visible identically as in the tableting materials without the active ingredient, 
which means that values are always higher in the concentration of 50 % of hypromellose; 
no difference is again observed within the type of hypromellose (30 % of Methocel p = 
0.373; 50 % of Methocel p = 0.191).
Values of the energy of precompression E1 in the tableting materials without the active 
ingredient are higher and more equalized in the case of Prosolv SMCC 90. In the case of 
Disintequik MCC 25, the same influence is observed as in the Emax values, which means 
higher values for a 50 % concentration of both types of Methocel and an insignificant dif-
ference within the type of Methocel used (30 % of Methocel p = 0.074; 50 % of Methocel p = 
0.089). As far as the tableting materials with tramadol are concerned, the E1 values in the 
tableting materials with Prosolv SMCC 90 are higher and more equalized than in the 
tableting materials with Disintequik MCC 25; tramadol decreases them slightly. In the case 
of tableting materials with Disintequik MCC 25, higher values are seen again in the case 
of a 50 % concentration of both Methocel types and the addition of tramadol slightly de-
creases them. Another parameter under evaluation was the energy of compression Ecom, 
which includes the energy accumulated in the tablet after compression, or the energy of 
plasticity (E2) and also the energy released during the decompression, or the energy of 
Table II. Tableting materials with Prosolv SMCC 90: values of energy profiles of compression and plasticity 
(n = 10)
Tableting 
material Emax ± SD (J) E1 ± SD (J) E2 ± SD (J) E3 ± SD (J) Ecom ± SD (J) PI ± SD (%)
1 11.24 ± 0.34 6.09 ± 0.33 4.51 ± 0.05 0.65 ± 0.01 5.16 ± 0.05 87.40 ± 0.12
2 10.81 ± 0.14 6.06 ± 0.12 4.09 ± 0.04 0.67 ± 0.01 4.75 ± 0.04 85.99 ± 0.06
3 10.88 ± 0.44 5.69 ± 0.40 4.54 ± 0.04 0.65 ± 0.01 5.19 ± 0.04 87.50 ± 0.11
4 10.69 ± 0.20 5.90 ± 0.21 4.12 ± 0.04 0.67 ± 0.01 4.79 ± 0.04 86.00 ± 0.11
5 12.81 ± 0.30 6.68 ± 0.29 5.47 ± 0.02 0.66 ± 0.01 6.13 ± 0.02 89.26 ± 0.06
6 12.68 ± 0.18 6.97 ± 0.17 5.02 ± 0.04 0.69 ± 0.01 5.71 ± 0.04 88.00 ± 0.19
7 13.04 ± 0.08 6.95 ± 0.10 5.42 ± 0.05 0.66 ± 0.01 6.08 ± 0.06 89.16 ± 0.05
8 12.79 ± 0.16 7.12 ± 0.16 4.99 ± 0.03 0.68 ± 0.01 5.67 ± 0.03 88.01 ± 0.09
Emax – total energy; E1 – energy of precompression; E2 – energy of plastic deformation; E3 – energy of elastic deformation; 
Ecom – energy of compression; Pl – plasticity; SD – standard deviation
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elasticity (E3). In the tableting materials without active ingredients, higher values are ob-
served in the tableting materials with Prosolv SMCC 90 and this time higher values are 
observed in these tableting materials for 30 % concentration of both types of Methocel, the 
same concentration of both types of Methocel showing practically the same values (30 % 
of Methocel p = 0.231; 50 % of Methocel p = 0.266). In the tableting materials with Disinte-
quik MCC 25, no statistically significant difference was recorded between the Ecom values 
in the case of Methocel K100M (p = 0.293). The Ecom values in the tableting materials with 
Prosolv SMCC 90 are decreased by tramadol, but in both cases they are higher for the 30 
% concentration of both types of Methocel. The Ecom values for the tableting materials 
with Disintequik MCC 25 are again lower for the tableting materials with tramadol. High-
er values are observed in the mixtures containing Methocel in the 50 % concentration, this 
influence not being observed in the tableting materials without the active ingredient. Plas-
ticity values in the tableting materials with Disintequik MCC 25 are slightly lower as well 
as the values with 50 % of both types of Methocel in the tableting materials with both types 
of dry binders. Plasticity in the tableting materials with Prosolv SMCC 90 and tramadol 
shows slightly lower values than in the tableting materials without the active ingredient; 
the values are also slightly higher in the presence of 30 % of both types of Methocel. Tablet-
ing materials with Disintequik MCC 25 and tramadol also possess slightly lower values of 
plasticity than the tableting materials without the active ingredient, but different effects of 
Methocel K100M concentrations are not observed in them (p = 0.393).
Tensile strength of tablets
The tensile strength values of tablets are shown in Figs. 1–3. Fig. 1 compares these 
values for all tableting materials without the active ingredient. The Figure shows lower 
Table III. Tableting materials with Disintequik MCC 25: values of energy profiles of compression and 
plasticity (n = 10)
Tableting 
material Emax ± SD (J) E1 ± SD (J) E2 ± SD (J) E3 ± SD (J) Ecom ± SD (J) PI ± SD (%)
9 7.24 ± 0.14 3.50 ± 0.13 3.14 ± 0.04 0.60 ± 0.01 3.74 ± 0.04 83.93 ± 0.16
10 8.57 ± 0.21 4.68 ± 0.19 3.26 ± 0.04 0.64 ± 0.01 3.90 ± 0.04 83.59 ± 0.13
11 7.29 ± 0.12 3.58 ± 0.10 3.11 ± 0.03 0.60 ± 0.01 3.71 ± 0.03 83.83 ± 0.17
12 8.79 ± 0.15 4.85 ± 0.13 3.30 ± 0.03 0.64 ± 0.01 3.94 ± 0.03 83.81 ± 0.16
13 7.90 ± 0.22 3.56 ± 0.18 3.75 ± 0.04 0.59 ± 0.01 4.34 ± 0.04 86.46 ± 0.10
14 9.25 ± 0.13 4.84 ± 0.13 3.79 ± 0.02 0.63 ± 0.01 4.41 ± 0.02 85.73 ± 0.05
15 8.26 ± 0.11 3.87 ± 0.10 3.80 ± 0.01 0.59 ± 0.01 4.38 ± 0.01 86.60 ± 0.06
16 9.45 ± 0.14 5.08 ± 0.15 3.74 ± 0.02 0.63 ± 0.01 4.37 ± 0.02 85.57 ± 0.13
Emax – total energy; E1 – energy of precompression; E2 – energy of plastic deformation; E3 – energy of elastic deformation; 
Ecom – energy of compression; Pl – plasticity; SD – standard deviation
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strength of tablets with Disintequik MCC 25. The tablets are stronger with a higher viscos-
ity degree of hypromellose, i.e., Methocel Premium K100M, in the case of both coprocessed 
dry binders. The opposite effect of concentrations of both types of Methocel in combina-
Fig. 1. Tensile strength of tablets at the compression force of 5 kN (n = 10): Tableting materials without 
active ingredient. P 90 – Prosolv SMCC 90; D 25 – Disintequik MCC 25; M4M – Methocel K4M Pre-
mium CR; M100M – Methocel K100M Premium CR; Mgst – magnesium stearate.
Fig. 2. Tensile strength of tablets at the compression force of 5 kN (n = 10): Tableting materials with 
Prosolv SMCC 90. P 90 – Prosolv SMCC 90; M4M – Methocel K4M Premium CR; M100M – Methocel 
K100M Premium CR; Mgst – magnesium stearate; T – tramadol.
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tion with the employed coprocessed dry binders is interesting. Thus, in the case of Prosolv 
SMCC 90, the tablets with a 30 % concentration of both types of Methocel are stronger, 
whereas in the case of Disintequik MCC 25, tablets with a 50 % concentration of both types 
of Methocel are stronger. The strength of tablets of all tableting materials with Prosolv 
SMCC 90 is represented in Fig. 2. This figure shows a decrease in the strength of tablets 
due to the addition of tramadol, but also equalization of the strength of tablets for all com-
positions used (p = 0.252). In the case of the tableting materials with Disintequik MCC 25, 
there is also a decrease in the strength of tablets by the action of tramadol, tablets with 50 
% of both types of Methocel remaining stronger (Fig. 3).
CONCLUSIONS
Tableting materials with Proslov SMCC 90 were better compressible and showed bet-
ter compaction and consolidation properties of particles than tableting materials with Dis-
intequik MCC 25. The values of total energy of compression, plasticity and tensile strength 
of tablets were higher in the tableting materials with Prosolv SMCC 90. Tramadol de-
creased these values and in the tableting materials with Prosolv SMCC 90 it equalized the 
values of tablet strength for all compositions tested. Tablets were stronger with a higher 
viscosity degree of hypromellose, i.e., Methocel Premium K100M, in the case of both dry 
binders.
Acknowledgments. – The study was supported by the firms JRS Pharma, Kerry and Colorcon 
GmbH, which supplied the samples of the excipients tested.
Fig. 3. Tensile strength of tablets at the compression force of 5 kN (n = 10): Tableting materials with 
Disintequik MCC 25. D 25 – Disintequik MCC 25; M4M – Methocel K4M Premium CR; M100M – 
Methocel K100M Premium CR; Mgst – magnesium stearate; T – tramadol.
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